Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors

Fineline Cube Mar 6, 2026
Company Drug

Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial

Fineline Cube Mar 6, 2026
Company Deals

Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates

Fineline Cube Feb 26, 2025

Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...

Company Deals

Hansoh Pharmaceutical’s HS-10561 Receives NMPA Clearance for Chronic Spontaneous Urticaria

Fineline Cube Feb 26, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received clinical trial...

Company Medical Device

J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China

Fineline Cube Feb 26, 2025

Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...

Company Deals

Thermo Fisher to Acquire Solventum’s Purification Business for USD 4.1B

Fineline Cube Feb 26, 2025

Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration...

Company Drug

J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment

Fineline Cube Feb 26, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...

Company Drug

Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy

Fineline Cube Feb 26, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...

Company Drug

YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial

Fineline Cube Feb 26, 2025

YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...

Company Deals

HQ Pharma and Shanghai Pharmaceuticals Expand Collaboration for Global Market Access

Fineline Cube Feb 26, 2025

China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai...

Company Deals

Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives

Fineline Cube Feb 26, 2025

China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have...

Company Drug

Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review

Fineline Cube Feb 26, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...

Company Deals

CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies

Fineline Cube Feb 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment...

Company Drug

Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients

Fineline Cube Feb 26, 2025

Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...

Company Drug

Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval

Fineline Cube Feb 26, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...

Company

MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study

Fineline Cube Feb 26, 2025

Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace,...

Company Deals

Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease

Fineline Cube Feb 26, 2025

US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD),...

Company Medical Device

Acotec Scientific’s Vericor Catheter Wins NMPA Approval for Peripheral Vascular Surgery

Fineline Cube Feb 25, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its peripheral disposable support catheter Vericor...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study

Fineline Cube Feb 25, 2025

China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...

Company Drug

Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US

Fineline Cube Feb 25, 2025

Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...

Company

CDE Includes Chiral Tech’s Cerdelga Generic in Rare Disease Care Plan

Fineline Cube Feb 25, 2025

China’s Center for Drug Evaluation (CDE) announced the inclusion of Beijing Chiral Tech’s generic version...

Company Medical Device

Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment

Fineline Cube Feb 25, 2025

US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration...

Posts pagination

1 … 171 172 173 … 631

Recent updates

  • Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors
  • Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial
  • Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration
  • HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds
  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s HLX97 Wins NMPA Phase I Approval – First-in-Class KAT6A/B Inhibitor Targets Advanced Solid Tumors

Company Drug

Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial

Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Company

HutchMed Reports $548.5 Million 2025 Revenue – FRUZAQLA Drives 26% Growth Amid China Market Headwinds

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.